menu
    • menu
    [{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"peptides","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dusquetide

    Menu

    Dusquetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Soligenix Begins Phase 2 Trial of SGX945 for Behçet’s Disease Treatment

                            Details : SGX945 (dusquetide) is a peptide, P62 inhibitor administered intravenously via infusion, which is being investigated for treating Aphthous Ulcers in Behçet's Disease.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dusquetide for the Treatment of Behcet's Disease

                            Details : Dusquetide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 26, 2024

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation for Dusquetide for Oral Lesions of Behçet's Disease

                            Details : SGX945 (dusquetide) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It is being evaluated in IND enabling studies for the treatment of oral lesions of Behçet's Disease.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 08, 2024

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to Dusquetide for Oral Lesions in Behcet's Disease

                            Details : SGX945 (dusquetide) is an innate defense regulator (p62 protein modulator), a new class of short, synthetic peptides. It is being evaluated for the treatment of lesions of Behçet's Disease

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 08, 2024

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulc...

                            Details : SGX945 (dusquetide) is a peptide inhibitor administered intravenously via infusion, which is being investigated for treating Aphthous Ulcers in Behçet's Disease.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            November 30, 2023

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

                            Details : SGX942 (dusquetide) is an innate defense regulator (IDR), short synthetic peptides, which modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response in conditions like oral mucositi...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 16, 2023

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies

                            Details : SGX942 (dusquetide), an innate defense regulator demonstrated positive results in reducing tumor size in both preclinical and clinical studies, also has received Fast Track Designation from the FDA for the treatment of oral mucositis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Soligenix Completes Enrollment in Phase 3 DOM-INNATE Trial of SGX942 to Treat Oral Mucositis

                            Details : Soligenix has completed patient enrollment in its Phase 3 DOM-INNATE ("Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity") study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Soligenix Gains Japanese Dusquetide Patent Allowance in Oral Mucositis

                            Details : The new claims cover therapeutic use of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 03, 2020

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Soligenix

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Th...

                            Details : SGX942 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 02, 2017

                            Lead Product(s) : Dusquetide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth